Glenmark Pharmaceuticals is planning a strategic shift to become a global innovation-led pharmaceutical company, with a focus on oncology drugs and a goal to submit an investigational new drug application for ISB 2301 later this year. The company has successfully transitioned from generics to innovation, highlighted by a significant licensing deal with AbbVie for ISB 2001, which has allowed it to repay its gross debt and supports its future growth plans.

Glenmark Pharmaceuticals has launched a generic version of Olanzapine injection in the United States, which is a bioequivalent alternative to Zyprexa intramuscular injection, aimed at expanding its injectable offerings and strengthening its presence in the institutional market.